← Back to Screener
Nuvectis Pharma, Inc. Common Stock (NVCT)
Price$9.54
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)44.96%
Price vs S&P 500 (4W)-18.10%
VGM Score65.41
Market Capitalization$253.05M
All Metrics
Book Value / Share (Quarterly)$0.54
P/TBV (Annual)9.99x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.69
Price vs S&P 500 (YTD)18.20%
EPS (TTM)$-1.20
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-1.20
EPS (Annual)$-1.21
ROI (Annual)-143.61%
Cash / Share (Quarterly)$0.95
ROA (Last FY)-83.39%
EBITD / Share (TTM)$-1.25
ROE (5Y Avg)-191.98%
Cash Flow / Share (Annual)$-0.62
P/B Ratio17.80x
P/B Ratio (Quarterly)14.40x
Net Income / Employee (Annual)$-2,034,000
ROA (TTM)-90.76%
EPS Incl Extra (Annual)$-1.21
Current Ratio (Annual)2.38x
Quick Ratio (Quarterly)2.27x
3-Month Avg Trading Volume0.07M
52-Week Price Return6.35%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.96
52-Week High$13.34
EPS Excl Extra (Annual)$-1.21
26-Week Price Return52.88%
Quick Ratio (Annual)2.38x
13-Week Price Return5.53%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.27x
Enterprise Value$227.92M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.23
3-Month Return Std Dev63.39%
Net Income / Employee (TTM)$-2,089,200
ROE (Last FY)-143.61%
EPS Basic Excl Extra (Annual)$-1.21
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.20
ROI (TTM)-147.78%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.97
Price vs S&P 500 (52W)-18.01%
Year-to-Date Return26.36%
5-Day Price Return-2.15%
EPS Normalized (Annual)$-1.21
ROA (5Y Avg)-117.72%
Month-to-Date Return-2.15%
Cash Flow / Share (TTM)$-1.03
EBITD / Share (Annual)$-1.26
ROI (5Y Avg)-191.98%
EPS Basic Excl Extra (TTM)$-1.20
P/TBV (Quarterly)8.51x
P/B Ratio (Annual)10.50x
Book Value / Share (Annual)$0.72
Price vs S&P 500 (13W)-2.72%
Beta-0.03x
Revenue / Share (TTM)$0.00
ROE (TTM)-147.78%
52-Week Low$5.55
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.26est. -0.32
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.17
4.17
4.17
4.09
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NVCTNuvectis Pharma, Inc. Common Stock | — | — | B | $9.54 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Nuvectis Pharma is a biopharmaceutical company focused on precision oncology. It develops novel, targeted small-molecule therapeutics for cancer patients with specific genetic profiles. The company's pipeline includes NXP800 and NXP900.